RT Journal Article
SR Electronic
T1 Pulmonary arterial hypertension: Long term effects of oral ambrisentan on clinical status, exercise capacity and haemodynamics
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P940
VO 40
IS Suppl 56
A1 Michele D'Alto
A1 Emanuele Romeo
A1 Paola Argiento
A1 Anna Correra
A1 Berardo Sarubbi
A1 Antonello D'Andrea
A1 Antonietta Caronna
A1 Maria Pignatiello
A1 Nicola Grimaldi
A1 Raffaele Calabrò
A1 Maria Giovanna Russo
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P940.abstract
AB Aim. To evaluate the efficacy and safety of oral ambrisentan in adult patients with pulmonary arterial hypertension (PAH) by assessing its long term effects on clinical status, exercise capacity and cardiopulmonary haemodynamics.Methods. This was a single-centre, open-label, single-arm, prospective study. Clinical status, resting transcutaneous oxygen saturation (SpO2), 6-minute walk distance, serology and RHC were assessed at baseline (before starting ambrisentan therapy) and at one year follow-up.Results. Twenty-seven consecutive adult patients (18 female, age 51±11y) with PAH (15 with idiopathic, 7 with congenital heart disease-related and 5 with connective tissue-related PAH) were enrolled. No patient treated with ambrisentan developed aminotransferase concentrations >3 times the upper limit of normal. After 12±4 months of therapy, an improvement in clinical status, 6-minute walk distance, pro-brain natriuretic peptide and haemodynamics was observed.View this table:Clinical and haemodynamic variables at baseline and after oral ambrisentan therapy.Conclusions. Long term ambrisentan therapy is safe and well tolerated at 12-month follow-up, resulting in a significant improvement in clinical status, exercise capacity and cardiopulmonary heamodynamics.